Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 1658 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2013  |  Volume : 17  |  Issue : 7  |  Page : 307-309

Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis

1 Department of Endocrinology, Bharti Research Institute of Diabetes and Endocrinology Bharti Hospital, Karnal, India
2 Department of Endocrinology, Osmania Medical College, Hyderabad, India
3 Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, Munich, Germany
4 Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
5 Medical University of Silesia, Zabrze, Poland
6 Endocrinology and Metabolism, Juntendo University Graduate School of Medicine, Tokyo, Japan
7 University of Indonesia, Jakarta, Indonesia
8 Bayer Healthcare, Global Medical Affairs, Beijing, China
9 The Third Affiliated Hospital of Sun Yat Sen University, Guangzhou, China
10 Bayer Healthcare, Bayer Zydus Pharma Private Limited, Thane, India

Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Research Institute of Diabetes and Endocrinology Bharti Hospital, Karnal, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.119634

Rights and Permissions

Alpha-glucosidase inhibitors are widely used especially in Asian countries as a treatment option for type 2 diabetes patients with high postprandial glycemia (PPG). The higher carbohydrate in the Indian diets lead to greater prandial glycemic excursion, increased glucosidase, and incretin activity in the gut and may need special therapeutic strategies to tackle these glucose peaks. This is the subgroup analysis of Indian subjects who participated in the GlucoVIP study that investigated the effectiveness and tolerability of acarbose as add-on or monotherapy in a range of patients with type 2 diabetes mellitus. A total of 1996 Indian patients were included in the effectiveness analysis. After 12.5 weeks (mean), the mean change in 2-hour PPG from baseline was −74.4 mg/dl, mean HbA1c decreased by -1.0%, and mean fasting blood glucose decreased by -37.9 mg/dl. The efficacy of acarbose was rated "very good" or "good" in 91.1% of patients, and tolerability as "very good" or "good" in 88.0% of patients. The results of this observational study suggest that acarbose was effective and well tolerated in the Indian patients with T2DM.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded391    
    Comments [Add]    
    Cited by others 3    

Recommend this journal